Income Statement

v3.21.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)        
Revenues, net $ 15,718 $ 33,695 $ 25,842 $ 70,590
Operating expenses:        
Cost of implants and other costs 1,796 27,510 2,428 50,444
Research and development 123,262 1,345,094 781,499 2,055,604
Selling, general and administrative 834,726 796,142 1,745,819 1,598,088
Depreciation and amortization 19,340 19,166 38,719 38,337
Total operating expenses 979,124 2,187,912 2,568,464 3,742,473
Loss from operations (963,406) (2,154,217) (2,542,622) (3,671,883)
Other income (expenses):        
Interest expense, net (126,849) (125,628) (250,157) (251,035)
Grant income 28,350 1,541,366 118,582 2,105,452
Other miscellaneous income 0 0 28,229 799
Total other income (expenses) (98,499) 1,415,738 (103,346) 1,855,216
Net loss before provision for income taxes (1,061,905) (738,479) (2,645,968) (1,816,667)
Income taxes 0 0 0 0
Net loss (1,061,905) (738,479) (2,645,968) (1,816,667)
Non-controlling interest 692 3,042 1,468 14,668
Net loss attributable to BioCorRx Inc. $ (1,061,213) $ (735,437) $ (2,644,500) $ (1,801,999)
Net loss per common share, basic and diluted $ (0.16) $ (0.14) $ (0.42) $ (0.34)
Weighted average number of common shares outstanding, basic and diluted 6,617,970 5,364,623 6,320,022 5,349,880

Source